Cargando…
Irbesartan ameliorates myocardial fibrosis in diabetic cardiomyopathy rats by inhibiting the TGFβ1/Smad2/3 pathway
Myocardial fibrosis (MF) is an important pathological change in diabetic cardiomyopathy. The aim of the present study was to investigate whether irbesartan serves a role in improving MF in a diabetic rat model. Fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), high-density lipo...
Autores principales: | Zong, Min, Zhao, Hua, Li, Qiang, Li, Yanbing, Zhang, Jianjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523283/ https://www.ncbi.nlm.nih.gov/pubmed/33005243 http://dx.doi.org/10.3892/etm.2020.9245 |
Ejemplares similares
-
Canagliflozin and irbesartan ameliorate renal fibrosis via the TGF-β1/Smad signaling pathway in Dahl salt-sensitive rats
por: Zhai, Jianlong, et al.
Publicado: (2023) -
Shenqiwan Ameliorates Renal Fibrosis in Rats by Inhibiting TGF-β1/Smads Signaling Pathway
por: Chen, Hongshu, et al.
Publicado: (2017) -
Follistatin Attenuates Myocardial Fibrosis in Diabetic Cardiomyopathy via the TGF-β–Smad3 Pathway
por: Wang, Yinhui, et al.
Publicado: (2021) -
Huangqi Shengmai Yin Ameliorates Myocardial Fibrosis by Activating Sirtuin3 and Inhibiting TGF-β/Smad Pathway
por: Pan, Jianheng, et al.
Publicado: (2021) -
Matrine suppresses cardiac fibrosis by inhibiting the TGF-β/Smad pathway in experimental diabetic cardiomyopathy
por: Zhang, Yong, et al.
Publicado: (2018)